SYDNEY, Oct. 12, 2026 /PRNewswire/ — Vopak Terminals Australia welcomes the New South Wales (NSW) Government’s endorsement of its proposed aviation fuel infrastructure expansion project in Port Botany. Included as a key project to strengthen the state’s fuel security and resilience^[1], the expansion reinforces Vopak’s commitment to providing robust, future-ready energy infrastructure.

Aligned with the government’s fuel security goals, the expansion capacity of approximately 120,000 cbm will strengthen supply chain resilience to help protect consumers and businesses. Adding new storage tanks and pipeline connections to this independent infrastructure increases fuel storage capacity even more, while supporting sustainable aviation fuels (SAF) to drive the sector’s decarbonisation.

Through the Investment Delivery Authority’s (IDA) endorsement, the NSW Government will provide practical, non-financial support to remove delivery barriers, improve coordination across government and accelerate project delivery^[1].

“We are proud to receive the endorsement from the NSW Government. As the energy needs of New South Wales continue to evolve, it is critical that we invest in secure, reliable, and adaptable infrastructure. By expanding as an independent, open-access facility, this project will not only address fuel security issues, but boost market competition to the benefit of Australian consumers. Furthermore, with the capability to store SAF, we are laying vital groundwork for the country’s energy transition,” said Mats de Groot, Managing Director, Vopak Terminals Australia.

The project is subject to Final Investment Decision (FID) and regulatory planning conditions and approvals. For more information on the NSW Government’s announcement, please visit the ^[1] official ministerial release https://www.nsw.gov.au/ministerial-releases/five-projects-endorsed-strengthening-fuel-security.

About the Vopak Terminals Australia

Incorporated in 1994, Vopak Terminals Australia is a leading independent fuel import and distribution infrastructure provider, delivering vital storage and logistics solutions to support Australia’s energy security and supply chains. Operating major import and distribution facilities at Port Botany, Sydney, and East Arm Berrimah, Darwin, Vopak provides safe, reliable, and open-access infrastructure for a full spectrum of clean petroleum products. Vopak Terminals Australia is part of Royal Vopak, the world’s leading independent tank storage infrastructure company with a global network of terminals and over 400 years of history. For more information about Vopak terminal in Sydney, please visit https://www.vopak.com/terminals/vopak-terminal-sydney-site-b.

About Royal Vopak

Royal Vopak helps the world flow forward. At ports around the world, we provide storage and infrastructure solutions for vital products that enrich everyday life. These products include liquids and gases that provide energy for homes and businesses, chemicals for manufacturing products, and edible oils for cooking as well as electrical energy. For all of these, our worldwide network of terminals supports the global flow of supply and demand. For more than 400 years, Royal Vopak has been at the forefront of fundamental transformations. With a focus on safety, reliability, and efficiency, we create new connections and opportunities that drive progress. Now more than ever, our talented people are applying this mindset to support the energy transition. Together with our partners and customers, we are accelerating the development of infrastructure solutions for hydrogen, ammonia, CO₂, battery energy storage systems, and low-carbon fuels & feedstocks – paving the way to a more sustainable future. Vopak is listed on the Euronext Amsterdam and is headquartered in Rotterdam, the Netherlands. For more information, please visit www.vopak.com.

Commercial & Partnership Information:
Noor Sneep
noor.sneep@vopak.com

• New data show favorable outcomes with subcutaneous infliximab following intravenous infliximab interruption, regardless of prior antibody status, in adult patients with moderate to severely active Crohn’s disease and ulcerative colitis
• Late-breaking analysis shows significantly higher rates of clinical remission and improved endoscopic outcomes with subcutaneous versus intravenous infliximab in patients with ileum-dominant Crohn’s disease

JERSEY CITY, N.J., Oct. 12, 2026 /PRNewswire/ — Celltrion USA, Inc. today announced that two analyses evaluating ZYMFENTRA^® (infliximab-dyyb) will be presented in oral presentations on Oct. 13 and 14 at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting in Nashville, Tennessee. The data include a late-breaking pooled and propensity score-matched analysis comparing subcutaneous (SC) and intravenous (IV) infliximab in patients with ileum-dominant Crohn’s disease, as well as a post hoc analysis from the Phase 3 LIBERTY-CD and LIBERTY-UC studies assessing the impact of prior anti-drug antibody (ADA) status on clinical outcomes following SC infliximab 240 mg initiation after interruption of IV infliximab treatment.^[1,2]

“People living with inflammatory bowel disease (IBD) can have varied disease characteristics, presentations, and treatment histories that may shape a unique care pathway, and clinicians need evidence that reflects the range of patients they see,” said Dr. Juby Jacob-Nara, Senior Vice President and Chief Medical Officer at Celltrion USA. “We’re pleased to share new analyses at ACG that provide additional information about subcutaneous infliximab in Crohn’s disease and ulcerative colitis and reflect Celltrion’s commitment to advancing clinically meaningful research for the IBD community.”

Presentation Details
Both analyses will be presented by Marla Dubinsky, M.D., Professor of Pediatrics and Director of the IBD Center at the Icahn School of Medicine, Mount Sinai, New York.

Post Hoc Analysis of LIBERTY-CD and -UC Studies Following an IV Infliximab Treatment Interruption
Date: Tuesday, Oct. 13, from 2:45-2:55 p.m. CT
Room: Karl F. Dean Grand Ballroom A, Level 4
Abstract Title: “Impact of Prior Anti-drug Antibody Status on Clinical Outcomes Following Subcutaneous Infliximab Initiation After Intravenous Infliximab Interruption: A Post Hoc Analysis of LIBERTY-CD and -UC Studies”
Session: Plenary Session 3A: IBD
Presentation: 40

A separate post hoc analysis evaluated efficacy, serum infliximab concentrations, and immunogenicity among patients from the placebo arms of the Phase 3 LIBERTY-CD and LIBERTY-UC studies who initiated SC infliximab 240 mg every two weeks following an interruption in IV infliximab treatment. Patients were assessed according to whether anti-drug antibodies (ADAs) had been detected before they began SC infliximab.^[2]

Among patients who initiated SC infliximab 240 mg, 72.5% (37 of 51) of patients with Crohn’s disease and 92.2% (71 of 77) of patients with ulcerative colitis had prior ADA positivity. The median interval between the last IV infliximab infusion and initiation of SC infliximab was 16 weeks in ADA-positive and ADA-negative patients in both the Crohn’s disease and ulcerative colitis groups.^[2]

Across Crohn’s disease and ulcerative colitis populations, the analysis found clinical outcomes were generally similar regardless of whether patients had ADAs before starting SC infliximab, with clinical response in Crohn’s disease and partial clinical response in ulcerative colitis observed by 8±2 weeks and sustained through 78 to 80 weeks. Serum infliximab concentrations increased after initiation of SC infliximab and were generally comparable over time across ADA-status groups. Levels of fecal calprotectin and C-reactive protein decreased at the first assessment after treatment began and remained lower through the final assessment. ADA positivity declined among patients with pre-existing ADAs, while new ADA development was uncommon in patients without prior ADAs.

“Anti-drug antibodies to intravenous infliximab can compromise infliximab reinitiation after treatment interruption. Data on subcutaneous infliximab initiation after a drug holiday are limited, particularly regarding the impact of prior ADA status on clinical outcomes,” said Marla Dubinsky, M.D., Professor of Pediatrics and Director of the IBD Center at the Icahn School of Medicine, Mount Sinai, New York. “These post hoc findings suggest that prior ADA status did not appear to compromise clinical outcomes after initiating subcutaneous infliximab following drug holiday after intravenous infliximab induction.”

Late-Breaking Data in Ileum-Dominant Crohn’s Disease
Date: Wednesday, Oct. 14, from 9:30-9:40 a.m. CT.
Late-Breaking Abstract Title: “Comparative Efficacy of Subcutaneous Versus Intravenous Infliximab in Ileum-Dominant Crohn’s Disease: A Pooled Analysis and Propensity Score-Matched Analysis of Infliximab Registrational Studies”
Session: Plenary Session 4B: Liver, Esophagus, CRC, IBD
Presentation: 72

The late-breaking abstract reports a pooled analysis of individual patient data from four infliximab registrational studies. The analysis included patients with ileal or ileocolonic Crohn’s disease who received standard maintenance treatment with SC infliximab 120 mg every two weeks or IV infliximab 5 mg/kg every eight weeks. Of 884 patients across the studies, 200 met the eligibility criteria; a 1:1 propensity score-matched analysis included 70 patients in each treatment group.^[1]

In the matched population at Week 54, patients receiving SC infliximab had higher rates of clinical remission, endoscopic response, and endoscopic remission than those receiving IV infliximab:^[1]

• Clinical remission: 71.4% vs. 51.4% (P = 0.023)
• Endoscopic response: 65.7% vs. 27.1% (P < 0.001)
• Endoscopic remission: 41.4% vs. 17.1% (P = 0.003)

The analysis also found that, in both treatment groups, endoscopic responders had significantly higher serum infliximab concentrations than nonresponders.

### 

About ZYMFENTRA^® (infliximab-dyyb; subcutaneous infliximab)
ZYMFENTRA^® (infliximab-dyyb) is a prescription medicine used as an injection under the skin (subcutaneous injection) by adults for the maintenance treatment of moderately-to-severely active ulcerative colitis following treatment with an infliximab product given by intravenous infusion (IV), Moderately-to-severely active Crohn’s disease following treatment with an infliximab product given by intravenous infusion (IV). ZYMFENTRA blocks the action of tumor necrosis factor-alpha (TNF-alpha), a protein that can be overproduced in response to certain diseases and cause the immune system to attack normal, healthy parts of the body.

ZYMFENTRA was approved by the FDA through the Biologics License Application (BLA) under the 351 (a) pathway of the Public Health Service Act (a “stand-alone” BLA). ZYMFENTRA is considered a new biologic with a first-approved subcutaneous administration form and thus will be under patent protection for its dosage form by 2037 and for its route of administration by 2040.

Indication and Important Safety Information

ZYMFENTRA^® is a prescription medicine indicated in adults for maintenance treatment of:

Moderately-to-severely active Crohn’s disease following treatment with an infliximab product administered intravenously.
Moderately-to-severely active ulcerative colitis following treatment with an infliximab product administered intravenously.
It is not known if ZYMFENTRA is safe and effective in children under 18 years of age.

What is the most important information I should know about ZYMFENTRA?

SERIOUS INFECTIONS

Patients treated with ZYMFENTRA are at increased risk for developing serious infections involving various organ systems and sites that may lead to hospitalization or death. Discontinue ZYMFENTRA if a patient develops a serious infection or sepsis.

Reported infections include:

• Active tuberculosis (TB), including reactivation of latent TB. Patients frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent TB before and during treatment with ZYMFENTRA. Treatment for latent infection should be initiated prior to treatment with ZYMFENTRA.
• Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients may present with disseminated, rather than localized, disease. Empiric anti-fungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness.
• Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria.

The risks and benefits of treatment with ZYMFENTRA should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection. Closely monitor patients for the development of signs and symptoms of infection during and after treatment with ZYMFENTRA, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy.

Risk of infection may be higher in patients greater than 65 years of age, patients with comorbid conditions and/or patients taking concomitant immunosuppressant therapy. In clinical trials, other serious infections observed in patients treated with infliximab included arthritis bacterial, pneumonia, and urinary tract infection.

MALIGNANCIES

Malignancies, some fatal, have been reported in children, adolescents, and young adults treated with TNF blockers, including infliximab products.

Approximately half of these cases were lymphomas, including Hodgkin’s and non-Hodgkin’s lymphoma. The other cases represented a variety of malignancies, including rare malignancies that are usually associated with immunosuppression and malignancies that are not usually observed in children and adolescents. The malignancies occurred after a median of 30 months after the first dose of therapy. Most of the patients were receiving concomitant immunosuppressants.

Post-marketing cases of hepatosplenic T-cell lymphoma, a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers, including infliximab products. These cases have had a very aggressive disease course and have been fatal. The majority of reported cases have occurred in patients with Crohn’s disease or ulcerative colitis, and most were in adolescent and young adult males. Almost all of these patients had received treatment with azathioprine or 6-mercaptopurine concomitantly with a TNF blocker at or prior to diagnosis. Carefully assess the risks and benefits of treatment with ZYMFENTRA, especially in these patient types.

In clinical trials of all TNF blockers, more cases of malignancies were observed compared with controls and the expected rate in the general population. In clinical trials of some TNF blockers, including infliximab products, more cases of other malignancies were observed compared with controls. As the potential role of TNF blocker therapy in the development of malignancies is not known, caution should be exercised when considering treatment of patients with a current or a past history of malignancy.

Melanoma and Merkel cell carcinoma have been reported in patients treated with TNF blocker therapy, including infliximab products. Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer.

CONTRAINDICATIONS

ZYMFENTRA is contraindicated in patients with a previous severe hypersensitivity reaction to infliximab-dyyb, other infliximab products, any of the inactive ingredients of ZYMFENTRA or any murine proteins (severe hypersensitivity reactions have included anaphylaxis, hypotension and serum sickness).

HEPATITIS B VIRUS REACTIVATION

TNF blockers, including infliximab products, have been associated with reactivation of hepatitis B virus (HBV) in patients who are chronic carriers. Some cases were fatal. Patients should be tested for HBV infection before initiating ZYMFENTRA. For patients who test positive, consult a physician with expertise in the treatment of hepatitis B. Exercise caution when prescribing ZYMFENTRA for patients identified as carriers of HBV and monitor closely for active HBV infection during and following termination of therapy with ZYMFENTRA. Discontinue ZYMFENTRA in patients who develop HBV reactivation and initiate antiviral therapy with appropriate supportive treatment. Exercise caution when considering resumption of ZYMFENTRA and monitor patients closely.

HEPATOTOXICITY

Hepatobiliary disorders, including acute liver failure, jaundice abnormal hepatic function, hepatic steatosis, hepatitis, hepatotoxicity, hyperbilirubinemia and non-alcoholic fatty liver, have been reported in patients receiving infliximab products post-marketing. Some cases were fatal or required liver transplant. Aminotransferase elevations were not noted prior to discovery of liver injury in many cases. Patients with symptoms or signs of liver dysfunction should be evaluated for evidence of liver injury. If jaundice and/or marked liver enzyme elevations (eg, ≥5 times the upper limit of normal) develop, ZYMFENTRA should be discontinued and a thorough investigation of the abnormality should be undertaken.

CONGESTIVE HEART FAILURE

Cases of worsening congestive heart failure (CHF) and new onset CHF have been reported with TNF blockers. Some cases had a fatal outcome. In several exploratory trials of other TNF blockers in the treatment of CHF, there were greater proportions of TNF-blocker-treated patients who had CHF exacerbations requiring hospitalization or increased mortality. ZYMFENTRA has not been studied in patients with a history of CHF and ZYMFENTRA should be used with caution in patients with CHF.

HEMATOLOGIC REACTION

Cases of leukopenia, neutropenia, thrombocytopenia and pancytopenia (some fatal) have been reported. The causal relationship to infliximab-product therapy remains unclear. Exercise caution in patients who have ongoing or a history of significant hematologic abnormalities. Advise patients to seek immediate medical attention if they develop signs and symptoms of blood dyscrasias or infection. Consider discontinuation of ZYMFENTRA in patients who develop significant hematologic abnormalities.

HYPERSENSITIVITY AND OTHER ADMINISTRATION REACTIONS

In post-marketing experience, serious systemic hypersensitivity reactions (including anaphylaxis, hypotension and serum sickness) have been reported following administration of infliximab products. If an anaphylactic or other clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue ZYMFENTRA.

INJECTION SITE REACTIONS

In clinical studies, localized injection-site reactions were reported following administration of ZYMFENTRA. If a clinically significant injection-site reaction occurs, institute appropriate therapy and discontinue ZYMFENTRA.

NEUROLOGIC REACTIONS

Agents that inhibit TNF have been associated with central nervous system (CNS) manifestation of systemic vasculitis, seizure and new onset or exacerbation of CNS demyelinating disorders, including multiple sclerosis and optic neuritis and peripheral demyelinating disorders, including Guillain-Barré syndrome. Exercise caution when considering ZYMFENTRA in patients with these disorders and consider discontinuation if these disorders develop.

RISK OF INFECTION WITH CONCURRENT ADMINISTRATION OF OTHER BIOLOGICS PRODUCTS

Serious infections and neutropenia have been reported with concurrent use of ZYMFENTRA with other immunosuppressive biological products. The concurrent use of ZYMFENTRA with other immunosuppressive biological products used to treat UC and CD may increase the risk of infection and is not recommended.

RISK OF ADDITIVE IMMUNOSUPPRESSIVE EFFECTS FROM PRIOR BIOLOGICAL PRODUCTS

Consider the half-life and mode of action of prior biological products to avoid unintended additive immunosuppressive effects when initiating ZYMFENTRA.

AUTOIMMUNITY

Treatment with TNF blockers may result in the formation of autoantibodies and in the development of a lupus-like syndrome. Discontinue ZYMFENTRA treatment if symptoms of a lupus-like syndrome develop.

VACCINATIONS AND USE OF LIVE VACCINES/THERAPEUTIC INFECTIOUS AGENTS

Prior to initiating ZYMFENTRA, update vaccinations in accordance with current vaccination guidelines. Live vaccines or therapeutic infectious agents should not be given with ZYMFENTRA due to the possibility of clinical infections, including disseminated infections. At least a 6-month waiting period following birth is recommended before the administration of any live vaccine to infants exposed in utero to ZYMFENTRA.

ADVERSE REACTIONS

In clinical trials with ZYMFENTRA, the most common adverse reactions occurring in ≥3% of ZYMFENTRA-treated patients included site reactions, COVID-19, anemia, arthralgia, infection site reaction, increased alanine aminotransferase and abdominal pain for UC, and COVID-19, headache, upper respiratory tract infection, injection site reaction, diarrhea, increased blood creatine phosphokinase, arthralgia, increased alanine aminotransferase, hypertension, urinary tract infection, neutropenia, dizziness and leukopenia for CD.

Please click for Full U.S. Prescribing Information.

Globally, prescribing information varies; refer to the individual country product label for complete information.

About American College of Gastroenterology (ACG)
The American College of Gastroenterology (ACG) is a recognized leader in educating GI professionals and the general public about digestive disorders. ACG’s mission is to advance world-class care for patients with gastrointestinal disorders through excellence, innovation, and advocacy in the areas of scientific investigation, education, prevention, and treatment. The 2026 ACG Annual Scientific Meeting & Postgraduate Course will convene in Nashville, Tennessee, from October 9 to 14, 2026. To learn more about ACG, visit website.

About Celltrion
Celltrion is a leading biopharmaceutical company that specializes in researching, developing, manufacturing, marketing and sales of innovative therapeutics that improve people’s lives worldwide. Celltrion is a pioneer in the biosimilar space, having launched the world’s first monoclonal antibody biosimilar. Our global pharmaceutical portfolio addresses a range of therapeutic areas including immunology, oncology, hematology, ophthalmology and endocrinology. Beyond biosimilar products, we are committed to advancing our pipeline with novel drugs to push the boundaries of scientific innovation and deliver quality medicines. For more information, please visit our website www.celltrion.com/en-us and stay updated with our latest news and events on our social media: LinkedIn, Instagram, X, and Facebook. 

About Celltrion USA
Celltrion USA is Celltrion’s U.S. subsidiary established in 2018. Headquartered in New Jersey, Celltrion USA is committed to expanding access to innovative biologics to improve care for U.S. patients. Celltrion’s FDA-approved biosimilar products in immunology, oncology, hematology, endocrinology and ophthalmology include: INFLECTRA^® (infliximab-dyyb), TRUXIMA^® (rituximab-abbs), HERZUMA^® (trastuzumab-pkrb), VEGZELMA^® (bevacizumab-adcd), YUFLYMA^®(adalimumab-aaty), AVTOZMA^® (tocilizumab-anho), STEQEYMA^® (ustekinumab-stba), STOBOCLO^® (denosumab-bmwo), OSENVELT^® (denosumab-bmwo), OMLYCLO^® (omalizumab-igec), and EYDENZELT^® (aflibercept-boav), as well as the novel biologic ZYMFENTRA^® (infliximab-dyyb). Celltrion USA will continue to leverage Celltrion’s unique heritage in biotechnology, supply chain excellence and best-in-class sales capabilities to improve access to high-quality biopharmaceuticals for U.S. patients. For more information, please visit www.celltrionusa.com and stay updated with our latest news and events on our social media – LinkedIn. 

FORWARD-LOOKING STATEMENT
Certain information set forth in this press release contains statements related to our future business and financial performance and future events or developments involving Celltrion Inc. and its subsidiaries that may constitute forward-looking statements, under pertinent securities laws. 
These statements may be also identified by words such as “prepares”, “hopes to”, “upcoming”, “plans to”, “aims to”, “to be launched”, “is preparing”, “once gained”, “could”, “with the aim of”, “may”, “once identified”, “will”, “working towards”, “is due”, “become available”, “has potential to”, the negative of these words or such other variations thereon or comparable terminology.
In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion Inc. and its subsidiaries’ management, of which many are beyond its control.
Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect to the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them. 
Such forward-looking statements necessarily involve known and unknown risks and uncertainties associated with the company’s business, including the risk factors disclosed in its Annual Report and/or Quarterly Reports, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such statements.
Celltrion Inc. and its subsidiaries undertake no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. 

Trademarks

ZYMFENTRA^® is a registered trademark of CELLTRION, Inc.

References

1. Dubinsky M, et al. Comparative Efficacy of Subcutaneous Versus Intravenous Infliximab in Ileum-Dominant Crohn’s Disease: A Pooled Analysis and Propensity Score-Matched Analysis of Infliximab Registrational Studies. Late-breaking abstract to be presented at the American College of Gastroenterology 2026 Annual Scientific Meeting; Oct. 11-14, 2026; Nashville, Tennessee. Abstract 72.
2. Dubinsky M, et al. Impact of Prior Anti-drug Antibody Status on Clinical Outcomes Following Subcutaneous Infliximab Initiation After Intravenous Infliximab Interruption: A Post Hoc Analysis of LIBERTY-CD and LIBERTY-UC Studies. Abstract to be presented at the American College of Gastroenterology 2026 Annual Scientific Meeting; Oct. 11-14, 2026; Nashville, Tennessee. Abstract 40.

For further information please contact:
Carly Scaduto,
cscaduto@jpa.com
202-591-4000

• New LEGO Ideas® challenge invites fans to create a first-of-its-kind cross-universe moment in LEGO bricks to celebrate iconic storytelling worlds of Star Wars™ and Marvel.
• The announcement was made at New York Comic Con during a panel featuring Kevin Smith; actor, director and Marvel Comics writer.
• Now open, fans can choose from three building themes – vehicles, characters, or scenes – to inspire the Star Wars and Marvel mash-up and submit via the LEGO Ideas platform.

NEW YORK, Oct. 12, 2026 /PRNewswire/ — Today at New York Comic Con (NYCC), the LEGO Group announced a first-of-its-kind LEGO® Ideas challenge. For the first time ever, fans are invited to mash-up Star Wars™ and Marvel by reimagining characters, vehicles and scenes from the two universes in LEGO form.

What’s more, the LEGO Ideas platform means that once the build has been submitted and fans have voted on the design, the favourite submissions will then become immortalised as an official LEGO product.

Fede Begher, Senior Vice President and Head of Product Group at the LEGO Group, said: “This challenge is a milestone for LEGO Ideas and our fan community. For the first time ever, fans can build with both Marvel and Star Wars in a single LEGO Ideas challenge, unlocking entirely new possibilities for creativity and storytelling. We know our fans never stop imagining new ways to bring their favourite worlds together, and we’re excited to see the originality, passion and innovation they bring to this unique crossover.”

As a tribute to the landmark 50^th anniversary of the Star Wars franchise in 2027, the Star Wars/Marvel: Hope Assembles comic series was unveiled this past summer. Launching in January, it’s the first-ever crossover between the Star Wars and Marvel Comics universes. The LEGO Ideas challenge celebrates that crossover and honours the 50^th anniversary.

Open from today, fans simply need to visit ideas.lego.com, choose from three challenge themes of mashing up Star Wars and Marvel vehicles, characters or scenes, review all challenge rules and guidelines, and then get building with LEGO elements. Voting for the submissions begins December 15, 2026, with the Grand Prize Selections being announced next year.

For more information, please visit ideas.lego.com/campaigns/hope-assembles.

About the LEGO Group
The LEGO Group’s mission is to inspire and develop the builders of tomorrow through the power of play. The LEGO System in Play, with its foundation in LEGO bricks, allows children and fans to build and rebuild anything they can imagine.

The LEGO Group was founded in Billund, Denmark in 1932 by Ole Kirk Kristiansen, its name derived from the two Danish words LEg GOdt, which mean “Play Well”.

Today, the LEGO Group remains a family-owned company headquartered in Billund. Its products are now sold in more than 120 countries worldwide.

For more information: www.LEGO.com

About the LEGO Ideas platform
LEGO Ideas offers fans the opportunity to submit their own brick creations with the chance to have their concept brought to life with the help of LEGO master designers and a share of the profits. Find out more at www.ideas.LEGO.com.

STAR WARS and related properties are trademarks and/or copyrights, in the United States and other countries, of Lucasfilm Ltd. and/or its affiliates. © & TM Lucasfilm Ltd.

© 2026 MARVEL

NBA legend Chris Bosh and Sir David Beckham visit NBA HOUSE to support Impact Week
Sharing the excitement of basketball event, inspiring care and uniting the community

MACAO, Oct. 11, 2026 /PRNewswire/ — As The NBA China Games 2026 entered its final day today, the five-day NBA Cares x Sands Cares Community Impact Week 2026 – co-organised by Sands China and NBA Cares – also drew to a successful close with its concluding event, the Community Basketball Carnival at NBA HOUSE at Halls A and B of Cotai Expo at The Venetian^® Macao.

The event brought together a line-up of sports icons, including NBA legend Chris Bosh – Basketball Hall of Fame Inductee and two-time NBA champion – together with Sands Global Ambassador Sir David Beckham, China women’s basketball national team player Zhang Ziyu, and China short track speed skating Olympic gold medalist Wang Meng, alongside members of Macau Special Olympics (MSO), families from Macao’s social service organisations, executives from Las Vegas Sands and Sands China, and Sands Cares Ambassadors. A total of around 200 participants gathered at NBA HOUSE to enjoy a series of basketball-themed carnival experiences and family-friendly activities, fostering meaningful exchanges among community stakeholders while promoting the inclusive power of sports.

The Impact Week fully demonstrates Sands China’s longstanding commitment to serving the Macao community through its Sands Cares spirit. By harnessing the synergies from this sports tourism event, the initiative not only unites strengths across various sectors of society to support Macao’s diversified development, but also extends its benefits into the local community to foster social inclusion.

The concluding event of the Impact Week began with a basketball clinic led by an NBA coach, who guided a group of MSO members through basketball skills training. Through demonstrations and personalized instruction, she helped participants enhance their basketball skills while encouraging them to challenge themselves, building self-confidence and fostering a spirit of inclusion in the process. In addition, NBA legend Chris Bosh, Zhang Ziyu and Wang Meng joined the event, engaging with MSO members on-site, adding to the warm and uplifting atmosphere. The MSO athletes exuded great enthusiasm throughout the session, underscoring the power of sport to break down barriers and foster inclusion.

Patrick Dumont, chairman of the board and chief executive officer of Las Vegas Sands Corp., and chairman of the board and non-executive director of Sands China Ltd., said: “Over the past few days, we have not only welcomed basketball fans from near and far to Macao through this world-class event, but also extended its impact beyond the arena through a wide range of community outreach initiatives during the Impact Week, including Greater Bay Area youth exchanges, a school visit, community engagement activities, and a basketball carnival. These initiatives enabled more Macao residents to experience the enthusiasm of basketball and the positive values it inspires.

“We firmly believe that world-class sporting events do more than enhance Macao’s international appeal. They create meaningful opportunities for youth development, cultural exchange, and community participation, demonstrating the power of sport to connect communities and bring people together, while ensuring the benefits of major events are shared across the community. Looking ahead, Sands China will continue to fully support the policy direction of the Macao SAR Government and further strengthen the synergy between tourism and sports. Through these efforts, we aim to further contribute to Macao’s economic diversification.”

Following his participation last year, Sands Global Ambassador Sir David Beckham once again joined this year’s Impact Week, where he engaged with families from Macao’s social service organisations, including the Macau Tung Sin Tong Charitable Society, the Macao Federation of Trade Unions, the General Union of Neighbourhood Associations of Macau, and The Women’s General Association of Macau. Alongside families of Sands China team members and Sands Cares Ambassadors, they took part in family-friendly activities, sharing joy and laughter together.

During the event, Sands Cares Ambassadors accompanied families from local social service organisations to explore NBA HOUSE, where they enjoyed a range of interactive attractions and experiences. Participants also received goodie bags assembled by NBA players, executives from Las Vegas Sands and Sands China, and Sands Cares Ambassadors, extending care and warm wishes to the wider community.

The “NBA Cares x Sands Cares Community Impact Week 2026” spanned five consecutive days, Oct. 7-11, featuring a diverse programme of activities focused on youth development, healthy living and community inclusion. Current NBA players and legends engaged with communities across Macao, with the initiative extending the impact of the NBA sporting event into the community and enabling more Macao residents to experience the positive energy and excitement generated by the world-class basketball event.

“NBA Cares x Sands Cares Community Impact Week 2026” is part of Sands Cares, the global corporate citizenship programme of Sands China’s parent company. As an important stakeholder in the Macao community, Sands China has actively fulfilled its corporate social responsibility for more than two decades. Through the programme, the company strives to connect with and serve the community, give back to society, and work alongside different sectors to build a more vibrant and inclusive Macao community.

For high resolution photos, please visit:

https://it-ezshare.sands.com.mo/exweb/share/c8ffbcd4-9b3e-4280-a99b-36cd64e1f440

About Sands China Ltd.

Sands China Ltd. (Sands China or the Company) is incorporated in the Cayman Islands with limited liability and is listed on The Stock Exchange of Hong Kong Limited (HKEx: 1928). Sands China is the largest operator of integrated resorts in Macao. The Company’s integrated resorts on the Cotai Strip comprise The Venetian^® Macao, The Plaza^® Macao, The Parisian^® Macao and The Londoner^® Macao. The Company also owns and operates Sands^® Macao on the Macao peninsula. The Company’s portfolio features a diversified mix of leisure and business attractions and transportation operations, including large meeting and convention facilities; a wide range of restaurants; shopping malls; world-class entertainment at The Venetian Arena, The Londoner Arena, The Venetian Theatre, The Parisian Theatre, The Londoner Theatre and Sands Theatre; and a high-speed Cotai Water Jet ferry service between Hong Kong and Macao. The Company’s Cotai Strip portfolio has the goal of contributing to Macao’s transformation into a world centre of tourism and leisure. Sands China is a subsidiary of global resort developer Las Vegas Sands Corp. (NYSE: LVS).

For more information, please visit www.sandschina.com.

Sands Cares

A firm believer in the importance of corporate social responsibility, Sands China Ltd. engages with the local Macao community as a part of Sands Cares – the charitable giving programme of parent company Las Vegas Sands Corp. Sands Cares integrates the company’s philanthropic work worldwide in four key areas: financial giving, community problem solving and collaboration, in-kind donations, and team member volunteerism.

Key areas of Sands Cares in Macao include the Sands Cares Ambassador programme for volunteering in the local community; charitable contributions to NGOs and community organisations; and sponsorship of community events.

For more information, please visit www.sands.com/sands-cares/.

About NBA Social Impact & Inclusion and NBA Cares

NBA Social Impact & Inclusion drives change on issues facing fans and communities by advancing needed resources and proven partners. We create data-driven strategies and programming to empower colleagues to bring their best self. NBA Cares works with NBA players and teams to highlight important issues through the NBA’s digital, social and broadcast channels, live events and partnerships.

Media contacts:

Corporate Communications, Sands China Ltd.

Mabel Wu
Tel: +853 8118 2268
Email: mabel.wu@sands.com.mo

Jesse Chiang
Tel: +853 8118 2054
Email: jesse.chiang@sands.com.mo